

Company Fact Sheet – 2026

Who we Are:	Nuvaira Inc. is a small, venture-backed medtech company founded in 2007 and based in Minneapolis, Minnesota. www.nuvaira.com
Product and Who we Treat:	The dNerva® Lung Denervation System is a novel, catheter-based system designed to treat airway nerve hyperactivity, a common pathological underpinning of COPD and asthma. dNerva therapy is being evaluated as the first targeted interventional treatment for small airways disease-dominant COPD.
Procedure:	dNerva lung denervation is a one-time outpatient procedure performed under general anesthesia in a bronchoscopy suite or OR by a trained interventional pulmonologist or advanced bronchoscopist. The TLD catheter is introduced into the lung via a standard therapeutic bronchoscope and the EsoCool catheter is placed in the esophagus for active cooling protection. Energy is delivered to ablate the vagal pulmonary nerves at the mainstem bronchi in both lungs, while continuous cooling protects the patient's airways and the esophagus, allowing the RF energy to safely penetrate to the depth of the pulmonary nerves – we call this DualCool(TM) Lung Denervation. The entire TLD procedure takes 60-80 minutes for treatment of both lungs, leaves no foreign body implants, and most patients return home the day of the procedure with standard post-bronchoscopy follow-up.
Clinical Trials:	To date over 500 patients in the USA and EU have been treated with TLD across 5 clinical trials, including two double-blind, randomized sham-controlled trials. Eighteen peer reviewed publications document therapy mechanism of action, a positive long-term safety profile and sustained positive clinical impact of lung denervation in patients with COPD. The AIRFLOW-3 trial was the largest interventional device trial ever conducted in COPD, at 464 patients, allowing a robust post-hoc analysis of responder criteria which are being prospectively evaluated in the AIRFLOW-4 investigational, randomized, controlled pivotal trial that will complete enrollment of 200 patients in 2027.
Therapeutic Value Proposition:	The goal of dNerva treatment is to improve lung function, reduce breathlessness, and decrease exacerbations in moderate-to-severe COPD patients with high symptom burden despite routine COPD drug therapy. As a one-time outpatient procedure, dNerva therapy has the potential to deliver durable clinical benefit without reliance on patient adherence, reducing economic and medical burden on patients, providers, and the healthcare system.
Regulatory Status:	FDA Investigational Device Exemption (IDE) approval for the AIRFLOW-4 Clinical Trial (2025)
Intellectual Property:	+ 75 patents issued and pending worldwide
Media Inquiries:	Amy Wolter +1 (763) 450-5676 info@nuvaira.com

###

In the US, the Nuvaira Lung Denervation System is limited by federal law to investigational use only. Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.